| 词条 | Rociletinib |
| 释义 |
| IUPAC_name = N-(3- | image = Rociletinib.svg | alt = | caption = | pronounce = | tradename = Xegafri | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category = | routes_of_administration = By mouth | legal_AU = | legal_AU_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = Investigational | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1374640-70-6 | class = | ATCvet = | ATC_prefix = L01 | ATC_suffix = XE37 | PubChem = 57335384 | DrugBank =DB11907 | ChemSpiderID = 30646712 | UNII = 72AH61702G | KEGG = D10858 | synonyms = CO-1686, AVL-301 | chemical_formula = | C=27 | H=28 | F=3 | N=7 | O=3 | smiles = CC(=O)N1CCN(CC1)c2ccc(c(c2)OC)Nc3ncc(c(n3)Nc4cccc(c4)NC(=O)C=C)C(F)(F)F | StdInChI=1S/C27H28F3N7O3/c1-4-24(39)32-18-6-5-7-19(14-18)33-25-21(27(28,29)30)16-31-26(35-25)34-22-9-8-20(15-23(22)40-3)37-12-10-36(11-13-37)17(2)38/h4-9,14-16H,1,10-13H2,2-3H3,(H,32,39)(H2,31,33,34,35) | StdInChIKey = HUFOZJXAKZVRNJ-UHFFFAOYSA-N }}Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.[1] It was being developed by Clovis Oncology as a potential treatment for non-small-cell lung cancer.[1] In May 2016, development of rociletinib was halted, along with its associated clinical trials, and Clovis Oncology withdrew its marketing authorisation application from the European Medicines Agency.[1] References1. ^1 2 {{cite journal|doi=10.2147/OTT.S97644|pmc=5063481|title=New developments in the management of non-small-cell lung cancer, focus on rociletinib: What went wrong?|journal=OncoTargets and Therapy|pages=6065|year=2016|last1=Van Der Steen|first1=Nele|last2=Caparello|first2=Chiara|last3=Rolfo|first3=Christian|last4=Pauwels|first4=Patrick|last5=Peters|first5=Godefridus|last6=Giovannetti|first6=Elisa|pmid=27785053|volume=9}} {{Extracellular chemotherapeutic agents}}{{antineoplastic-drug-stub}} 4 : Acrylamides|Trifluoromethyl compounds|Receptor tyrosine kinase inhibitors|Abandoned drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。